Ruxolitinib

Generic Name
Ruxolitinib
Brand Names
Jakafi, Jakavi, Opzelura
Drug Type
Small Molecule
Chemical Formula
C17H18N6
CAS Number
941678-49-5
Unique Ingredient Identifier
82S8X8XX8H
Background

Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...

Indication

Ruxolitinib is indicated for the treatment of the following conditions:

Topical ruxolitinib is indicated for:

Associated Conditions
Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
Associated Therapies
-
Clinical Trials
Related News

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Phase 2
Completed
Conditions
Myelofibrosis
Interventions
Drug: Ruxolitinib
First Posted Date
2011-04-22
Last Posted Date
2014-03-10
Lead Sponsor
Incyte Corporation
Target Recruit Count
41
Registration Number
NCT01340651

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Phase 1
Completed
Conditions
Myelofibrosis
Interventions
Drug: Ruxolitinib
First Posted Date
2011-03-17
Last Posted Date
2022-03-09
Lead Sponsor
Incyte Corporation
Target Recruit Count
69
Registration Number
NCT01317875

Phase l/II Study of Ruxolitinib for Acute Leukemia

Phase 1
Terminated
Conditions
Leukemia
Interventions
Drug: Ruxolitinib
First Posted Date
2010-12-02
Last Posted Date
2024-05-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
27
Registration Number
NCT01251965
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

First Posted Date
2009-08-06
Last Posted Date
2018-03-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
309
Registration Number
NCT00952289

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

First Posted Date
2009-07-08
Last Posted Date
2019-08-19
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
219
Registration Number
NCT00934544
Locations
🇬🇧

Novartis Investigative Site, Oxford, United Kingdom

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Phase 2
Terminated
Conditions
Myeloproliferative Neoplasm (MPN)
Interventions
Drug: Ruxolitinib
First Posted Date
2008-07-31
Last Posted Date
2019-10-28
Lead Sponsor
Incyte Corporation
Target Recruit Count
73
Registration Number
NCT00726232

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
Drug: Ruxolitinib
First Posted Date
2008-03-19
Last Posted Date
2018-02-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
22
Registration Number
NCT00638378

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Ruxolitinib
First Posted Date
2008-02-18
Last Posted Date
2022-02-08
Lead Sponsor
Incyte Corporation
Target Recruit Count
25
Registration Number
NCT00617994

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

First Posted Date
2007-08-01
Last Posted Date
2018-03-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
154
Registration Number
NCT00509899

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

First Posted Date
2002-08-26
Last Posted Date
2024-12-19
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
60
Registration Number
NCT00044304
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy